This is a summary report on the panel discussion at the TOPRA Symposium 2020. The panel discussed how the EMA and national regulatory agencies will ensure innovation and patients remain at the heart of the pharmaceutical strategy for the next decade. The panelists acknowledged to maintain a competitive position, EU pharma needs to embrace digital transformation by ensuring the scientific community has access to, and the capacity to analyze EU healthcare data. Guido Rasi, Executive Director, EMA, presented the “EMA Regulatory Science to 2025” which focuses on five goals, including the necessity to address emerging health threats, the leveraging of research and innovation in EMA processes, and driving collaborative evidence generation.
Published on: Nov 17, 2020
Download the full publication now
Fill in the form to download the content
All our resources 
